MedTrace Logo

Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas

NCT00750386 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2011-05-23

No results posted yet for this study

Summary

This trial will determine the feasibility and toxicity of dose intense (every 2 weeks) of paclitaxel+carboplatin combination following cytoreductive surgery in patients with stage Ic-IV ovarian cancer.

Conditions

Interventions

DRUG

Paclitaxel

175 mg/m2, I.V, every 2 weeks

DRUG

Carboplatin

Carboplatin AUC, I.V, 5 every 2 weeks

Sponsors & Collaborators

  • University Hospital of Crete

    collaborator OTHER

  • Hellenic Oncology Research Group

    lead OTHER

Principal Investigators

  • Christos Emmanouilides, MD · Interbalkan Hospital, division of Oncology, Pylaia, Thessaloniki

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00750386 on ClinicalTrials.gov